JATT III Acquisition Corp prices $60 million IPO for biotech focus
- JATT III Acquisition Corp priced its IPO at $10.00 per share for 6,000,000 ordinary shares
- Gross proceeds from the offering total $60,000,000
- Shares will trade on Nasdaq Capital Market under ticker JTTT starting August 26, 2026
- Guggenheim Securities acted as sole book-running manager with a 45-day over-allotment option
- Company focuses on biotechnology and life sciences businesses using data-driven approaches
*this image is generated using AI for illustrative purposes only.
JATT III Acquisition Corp priced its initial public offering of 6,000,000 ordinary shares at $10.00 per share on August 25, 2026. The transaction raises gross proceeds of $60,000,000 for the Cayman Islands exempted company.
The ordinary shares are scheduled to begin trading on the Nasdaq Capital Market under the ticker symbol "JTTT" on August 26, 2026. The offering is expected to close on August 27, 2026, subject to customary closing conditions.
Offering Structure and Underwriting
Guggenheim Securities, LLC acted as the sole book-running manager for the deal. The underwriters hold a 45-day option to purchase up to 900,000 additional ordinary shares at the IPO price to cover over-allotments.
| Metric | Detail |
|---|---|
| Shares Offered | 6,000,000 ordinary shares |
| Offering Price | $10.00 per share |
| Gross Proceeds | $60,000,000 |
| Over-allotment Option | 900,000 shares |
| Ticker Symbol | JTTT |
| Exchange | Nasdaq Capital Market |
A registration statement for the securities was declared effective by the U.S. Securities and Exchange Commission on August 25, 2026. Copies of the prospectus are available from Guggenheim Securities, LLC.
Strategic Focus and Management
JATT III Acquisition Corp is a blank check company formed to pursue a merger, amalgamation, or similar business combination. While it may target any industry, the company intends to focus primarily on healthcare-related businesses, with an emphasis on biotechnology and life sciences.
The management team plans to seek businesses utilizing data-driven approaches, including machine learning and computational biology, to improve therapeutic discovery. The company aims to provide these targets with access to public markets for funding development and strategic transactions.
Dr. Someit Sidhu serves as Chief Executive Officer and Chairman of the Board. Nicholas Fernandez is the Chief Financial Officer. The Board of Directors also includes Verender S. Badial, Arjun Goyal, Jonathon Kluft, and Christopher Staral.
The company is sponsored by JATT Ventures III L.P. It has not selected a specific business combination target nor engaged in substantive discussions with any potential target.
How might the current interest rate environment and investor appetite for biotech SPACs impact JATT III's ability to secure a target within its typical two-year window?
What specific criteria will Dr. Someit Sidhu and the management team prioritize when evaluating potential targets in the computational biology and machine learning sectors?
Given Guggenheim Securities' role as sole book-running manager, how does their track record in healthcare deals influence the perceived credibility of JATT III among institutional investors?
16
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
